About PGxl
PGXL is an internationally recognized pioneer in the application of molecular diagnostics to pharmacogenetics and is the first laboratory to be CLIA-certified specifically for pharmacogenetics testing. The company was founded in 2005 by Dr. Roland Valdes, Jr., and Dr. Mark W. Linder, researchers who are among the worldwide thought leaders in the science underlying personalized medicine. Our scientists are leading the way in the incorporation of genetic information into the practice of medicine.
News
-
PGXL Technologies to Add Single-Cell Sorting Technology
We're adding Silicon Biosystems' DEPArrayTM to our already impressive set of capabilities. DEPArray is a technology that allows researchers to sort ...
-
Patent No Longer Pending
The United States Patent and Trade Office has issued patent number 8380539 for PerMIT, PGXL's decision support software. The application ...
-
PGXL Announces National Distribution Deal
PGXL Laboratory and Essential Molecular Testing Corporation have formed a long term distribution agreement. The strategic alliance, PGXL Partners, gives ...
-
PerMIT Works: The Age of Companion Informatics Begins
Thrombosis and Haemostasis has published the study we alluded to earlier. The first release of hard data from ongoing trials ...
PGxl Blog
-
Supreme Court Rules on Gene Patents
The Supreme Court's decision to invalidate patents on human genes changes the landscape of Personalized Medicine, making it possible for more ...
-
FDA: Genetics Requires New Clinical Trial Model
The FDA advocates the development of a new method of clinical trials to accomodate genetic information. Instead of embarking on traditional ...
-
Medicare Specifies PGx CPT Codes
Medicare recently issued specific CPT codes for many of the tests performed by PGXL. Now the agency is struggling with ...
-
More DEPArray/PGXL Technologies
Business First picked up the news that PGXL Technologies is adding the DEPArray. It's a nice little backgrounder aimed at ...